Invivyd, Inc. Files 8-K

Ticker: IVVD · Form: 8-K · Filed: Oct 6, 2025 · CIK: 1832038

Invivyd, INC. 8-K Filing Summary
FieldDetail
CompanyInvivyd, INC. (IVVD)
Form Type8-K
Filed DateOct 6, 2025
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, corporate-information

TL;DR

Invivyd filed a routine 8-K, no new info.

AI Summary

Invivyd, Inc. filed an 8-K on October 6, 2025, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is incorporated in Delaware and has its principal executive offices in New Haven, CT. The filing does not disclose specific financial figures or material events beyond its routine reporting nature.

Why It Matters

This 8-K filing indicates Invivyd, Inc. is fulfilling its regulatory reporting obligations. It confirms the company's legal structure and location but does not provide new operational or financial information.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not contain any new material information that would indicate a change in risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Invivyd, Inc.?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of October 6, 2025.

When was Invivyd, Inc. formerly known as?

Invivyd, Inc. was formerly known as Adagio Therapeutics, Inc., with a date of name change on November 12, 2020.

Where are Invivyd, Inc.'s principal executive offices located?

Invivyd, Inc.'s principal executive offices are located at 209 Church Street, New Haven, CT 06510.

What is the state of incorporation for Invivyd, Inc.?

Invivyd, Inc. is incorporated in Delaware.

What is the telephone number listed for Invivyd, Inc.?

The telephone number listed for Invivyd, Inc. is (781) 819-0080.

Filing Stats: 439 words · 2 min read · ~1 pages · Grade level 10.3 · Accepted 2025-10-06 07:07:20

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events. On October 6, 2025, Invivyd, Inc. issued a press release entitled "Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID." A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated October 6, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INVIVYD, INC. Date: October 6, 2025 By: /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing